UKALL 2011

Chief investigator - Professor Pamela Kearns, University of Birmingham
UK Acute Lymphoblastic Leukaemia Trials
Amount awarded: £1,200,303
Award start date: 01 Jan 2010
Recruitment start date: 26 Apr 2012
Award duration: 12 years

This trial is looking at treatment for children who have acute lymphoblastic leukaemia (ALL) or a type of non-Hodgkin lymphoma (NHL) called lymphoblastic lymphoma (LBL).

Children with ALL or LBL are usually given chemotherapy made up of a number of drugs in different combinations. But chemotherapy can be harsh, particularly in children, so doctors are always looking for ways to reduce the side effects. Researchers want to see if using standard drugs in slightly different ways can achieve the same results but with fewer side effects, and reduce the risk of the blood cancer from returning. For example, giving the steroid dexamethasone at a higher dose but in a shorter time for the induction treatment may decrease side effects, and giving methotrexate at a higher dose during maintenance phase may help prevent relapse.

The aim of this trial is to:

  • See if changing the standard treatment for children and young people with ALL or LBL will reduce side effects and help stop their disease from coming back

You may be eligible to join this trial if:

  • You have ALL or LBL
  • You are between 1 and 24 years old

Other eligibility criteria may apply.